Education
About Us
Working with TipRanks
Follow Us
Unicycive Therapeutics (UNCY)
NASDAQ:UNCY
Total Valuation
Unicycive Therapeutics has a market cap or net worth of $91.00M. The enterprise value is ―.
Market Cap$91.00M
Enterprise Value―
Share Statistics
Unicycive Therapeutics has 120,629,280 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding120,629,280
Owned by Insiders11.70%
Owned by Institutions36.77%
Financial Efficiency
Unicycive Therapeutics’s return on equity (ROE) is 8.02 and return on invested capital (ROIC) is 692.93%.
Return on Equity (ROE)8.02
Return on Assets (ROA)-2.15
Return on Invested Capital (ROIC)692.93%
Return on Capital Employed (ROCE)6.21
Revenue Per Employee30.68K
Profits Per Employee-1.39M
Employee Count22
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Unicycive Therapeutics is -0.70. Unicycive Therapeutics’s PEG ratio is -0.19.
PE Ratio-0.70
PS Ratio0.00
PB Ratio1.84
Price to Fair Value-5.59
Price to FCF-2.25
Price to Operating Cash Flow-1.93
PEG Ratio-0.19
Income Statement
In the last 12 months, Unicycive Therapeutics had revenue of 675.00K and earned -30.54M in profits. Earnings per share was -1.28.
Revenue675.00K
Gross Profit675.00K
Operating Income-20.77M
Pretax Income-30.54M
Net Income-30.54M
EBITDA-30.18M
Earnings Per Share (EPS)-1.28
Cash Flow
In the last 12 months, operating cash flow was -26.47M and capital expenditures -50.00K, giving a free cash flow of -26.52M billion.
Operating Cash Flow-26.47M
Free Cash Flow-26.52M
Free Cash Flow per Share-0.22
Dividends & Yields
Unicycive Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.30
52-Week Price Change-4.55%
50-Day Moving Average0.61
200-Day Moving Average0.56
Relative Strength Index (RSI)48.95
Average Volume (3m)2.39M
Important Dates
Unicycive Therapeutics upcoming earnings date is Aug 18, 2025, TBA Not Confirmed.
Last Earnings DateMay 14, 2025
Next Earnings DateAug 18, 2025
Ex-Dividend Date―
Financial Position
Unicycive Therapeutics as a current ratio of 0.76, with Debt / Equity ratio of 2.90%
Current Ratio0.76
Quick Ratio0.76
Debt to Market Cap<0.01
Net Debt to EBITDA0.29
Interest Coverage Ratio-253.34
Taxes
In the past 12 months, Unicycive Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Unicycive Therapeutics EV to EBITDA ratio is -0.41, with an EV/FCF ratio of -0.68.
EV to Sales18.37
EV to EBITDA-0.41
EV to Free Cash Flow-0.68
EV to Operating Cash Flow-0.68
Balance Sheet
Unicycive Therapeutics has $32.35M in cash and marketable securities with $807.00K in debt, giving a net cash position of -$31.54M billion.
Cash & Marketable Securities$32.35M
Total Debt$807.00K
Net Cash-$31.54M
Net Cash Per Share-$0.26
Tangible Book Value Per Share-$0.16
Margins
Gross margin is 235.06%, with operating margin of -3077.63%, and net profit margin of -4525.04%.
Gross Margin235.06%
Operating Margin-3077.63%
Pretax Margin-4525.04%
Net Profit Margin-4525.04%
EBITDA Margin-4470.81%
EBIT Margin-4512.89%
Analyst Forecast
The average price target for Unicycive Therapeutics is $6.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.50
Price Target Upside1126.42% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-100.00%
EPS Growth Forecast52.65%